Project Grant R01CA292692
Award Date
7/15/24
Completion Date
6/30/29
Dollars Obligated
$485K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Tampa, FL 33612, USA
Similar Awards
This $568,538 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to investigate how the release of the cytokine interleukin-1 alpha during different cancer therapies, such as programmed necrosis and chemotherapies like paclitaxel, alters the immune response and creates an immunosuppressive tumor microenvironment. The research aims to understand the...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $103,948 to the Sloan-Kettering Institute for Cancer Research to investigate mechanisms driving T-cell dysfunction and impaired translation in the tumor microenvironment. The research aims to elucidate how local amino acid availability limits effector function in tumor-infiltrating T-cells and how enhancing amino acid transport could improve...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower Program (CFDA 93.398) provides $293,369 to Duke University to investigate the mechanisms by which residual tumor cells evade the immune system after treatment with targeted oncogene therapies. The researchers will use integrative transcriptomics and functional genomics approaches to uncover potential targets to enhance the immune-mediated clearance of these residual tumor cells. This research aims to elucidate...
This federal Project Grant award of $380,337 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to develop predictive models that relate mRNA sequence to stability and translation. The University of Washington will combine machine learning with massively parallel reporter assays to build these models, and then use innovative design algorithms to generate synthetic 5'UTR and coding sequences that result in either high protein expression across cell types or highly...
The National Cancer Institute (NCI) awarded a $377,102 Project Grant (CFDA 93.398 - Cancer Research Manpower) to The Johns Hopkins University on September 6, 2024. The award will fund a research project titled "Defining Protein Translation Dynamics in Cancers with Differential MYC Expression" over a period ending on March 31, 2027. The research aims to investigate the effects of MYC gene overexpression on protein translation dynamics, ribosome collision frequency, and sensitivity to...
The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $696,569 to New York University School of Medicine to conduct research aimed at developing novel therapies for lung cancer. The key objectives are to: 1) characterize the impact of the protein lipocalin 2 (LCN2) on the tumor microenvironment, 2) develop antibody-based therapeutics that interfere with LCN2 and assess their efficacy as monotherapy and in combination with immune checkpoint...
This Project Grant award for $176,712 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of Pittsburgh to investigate the role of CD91 receptor signaling in priming T cell responses to eliminate nascent, emerging tumors. The research aims to develop a new mouse model to test the importance of CD91-mediated signaling in response to tumor-derived heat shock proteins (HSPs) for cancer immunosurveillance. Specifically, the project will...
This federal Project Grant award of $400,000.00 was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Nuago Therapeutics Inc., a small disadvantaged business located in Chicago, IL. The funding supports the development of a short RNA therapeutic to treat ovarian cancer. The project aims to advance targeted cancer therapies, which have struggled to produce cures for solid cancers, through this innovative approach. The award period runs from June 9, 2025 to May...